Eczema Clinical Trial - Short-term Topical Application to Prevent Atopic

Status Completed

Clinical Trial Summary

This is a randomised, open-label, controlled study designed to investigate the effect of short-term neonatal skin barrier protection using a commercially available moisturiser on the prevention of atopic dermatitis and food allergy in high risk children.

Clinical Trial Description

Eczema, also known medically as Atopic Dermatitis (AD) is the most common skin disease of childhood, affecting 20% of Irish children, and is a general term for a group of skin conditions that cause the skin to become dry, red, itchy and inflamed. AD is often the first manifestation of atopic comorbidities including food allergy, asthma and allergic rhinitis. Recently published studies suggest that skin barrier preservation, with topically applied moisturisers in the first year of life, reduces the incidence of AD. Our own data suggests that an earlier window for this skin barrier protection may exist. This study is a randomised, open-label, controlled study and will investigate the effect of short-term neonatal skin barrier protection on the prevention of AD and food allergy in high risk infants. Infants with at least one parent with a positive history of atopic disease (AD, allergic rhinitis, asthma or food allergy) will be eligible for recruitment. The first study visit will take place within approximately 4 days of birth in the postnatal wards. At this visit, infants will be randomised to either treatment with skin barrier protection using a commercially available moisturiser or to standard routine skincare with no moisturiser from as soon as possible after birth until 2 months of age. This visit will also involve measurements of neonatal trans-epidermal water loss (TEWL) and natural moisturising factor (NMF) to assess skin barrier function and structure. Skin swabs will also be taken for microbiome and immune biomarker analysis. Follow-up assessments will take place at 2, 4 and 8 weeks, 6 and 12 months. Each visit will include a physical examination of the infant's skin, including TEWL and NMF measurements, and a questionnaire on infant health, bathing and skincare. Infant skin swabs will be taken again at 8 weeks and 12 months. A research nurse or doctor, blind to treatment allocation, will administer standardised assessments for the presence (yes/no), extent and severity of AD at 6 and 12 months. Suspected cases of food allergy will be investigated using skin prick testing (SPT) and oral food challenges. A DNA sample will be taken to test for filaggrin loss-of-function mutations, which are linked to AD risk. The primary outcome is AD at 12 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03871998
Study type	Interventional
Source	University College Cork
Contact
Status	Completed
Phase	N/A
Start date	April 16, 2019
Completion date	November 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03089476` - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy	N/A
Recruiting	`NCT05839405` - Food Allergy in the Brain
Completed	`NCT02552537` - iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions	Phase 4
Completed	`NCT01634737` - Crustacean Allergy and Dust Mites Sensitization	N/A
Completed	`NCT05072665` - Fast Allergy Sensitivity Test	N/A
Active, not recruiting	`NCT04887441` - Allergology: Information, Data and Knowledge Organization
Recruiting	`NCT03265262` - The Basophil Activation Test as a Diagnostic Tool in Pediatric Food Allergy	N/A
Completed	`NCT04186949` - Early Origins of Allergy and Asthma
Completed	`NCT02490007` - Pertussis Immunisation and Food Allergy
Recruiting	`NCT03151252` - Improvement of Foodallergy Diagnostic in Gastrointestinal Tract	N/A
Completed	`NCT02159833` - Intranasal Diagnostics in Food Allergy: a Feasibility Study	N/A
Completed	`NCT02377284` - Prevention and Management of Food Allergies	N/A
Completed	`NCT02354729` - Encouraging Allergic Young Adults to Carry Epinephrine	N/A
Completed	`NCT02640560` - One-year Survey of Anaphylaxis in Outpatient Children Allergic to Peanuts, Walnuts/Hazelnuts, Shellfish	N/A
Enrolling by invitation	`NCT06097572` - Improved Diagnostics in Food Allergy Study	N/A
Recruiting	`NCT04606615` - Skin Barrier Abnormalities and Oxidative Stress Response
Recruiting	`NCT05785299` - Clinical Versus Home Introduction of Milk in Children With Non-IgE-mediated Cow's Milk Allergy	N/A
Not yet recruiting	`NCT06112873` - Quality of Life in Food Allergy: Validation of Three Mini-questionnaires
Completed	`NCT03337802` - Effect of Mediterranean Diet During Pregnancy on the Onset of Overweight and Obesity in the Offspring	N/A
Not yet recruiting	`NCT06085118` - Observatory on Cow's Milk Protein Allergy

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Short-term Topical Application to Prevent Atopic Dermatitis — STOP AD

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms